Gliomas in patients with neurofibromatosistype

Expert Review of Neurotherapeutics

Volumn 9, Issue 4, 2009, Pages 535-539

  Albers, Anne C ^a   Gutman, David H ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Astrocytoma; Brain tumor; Brainstem glioma; Optic glioma; Pilocytic astrocytoma

Indexed keywords

CARBOPLATIN; CHLOROETHYLCYCLOEXYLNITROSOUREA; NITROSOUREA DERIVATIVE; PROCARBAZINE; TEMOZOLOMIDE; TIOGUANINE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ASTROCYTOMA; BRAIN DECOMPRESSION; BRAIN STEM; BRAIN STEM TUMOR; CANCER SURGERY; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; GLIOMA; HUMAN; HYPOTHALAMUS; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOLOGY; OPTIC NERVE; OPTIC PATHWAY GLIOMA; REVIEW; VISUAL IMPAIRMENT; BRAIN TUMOR;

BRAIN NEOPLASMS; GLIOMA; HUMANS; NEUROFIBROMATOSIS 1;

EID: 66349094869     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.4     Document Type: Review

References (26)

1. Friedman JM, Riccardi VM. Clinical and epidemiological features. In: Neurofibromatosis: Phenotype, Natural History and Pathogenesis (3rd Edition).Friedman JM, Gutmann DH, MacCollin M et al.(Eds). The Johns Hopkins University Press, Baltimore, USA and London, UK (1999). Comprehensive guide to the care and management of neurofibromatosis 1
2. NIH Consensus Development Conference. Neurofibromatosis. Arch. Neurol.45, 575-578 (1988).
3. Gutmann DH, Aylsworth A, Carey JC et al.The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA278(1), 51-57 (1997).
4. Guillamo JS, Creange A, Kalifa C et al.Prognostic factors of CNS tumors in neurofibromatosis 1(NF1): a retrospective study of 104 patients. Brain126, 152-160 (2003).
5. Matsui I, Taimura M, Kobayashi N et al.Neurofibromatosis type 1 and childhood cancer. Cancer72, 2746-2754 (1993).
6. Korf BR. Neurofibromas and malignant tumors of the peripheral nerve sheath. In: Neurofibromatosis: Phenotype, Natural History and Pathogenesis (3rd Edition).Friedman JM, Gutmann DH, MacCollin M et al.(Eds). The Johns Hopkins University Press, Baltimore, USA and London, UK (1999).
7. Korf BR. Plexiform neurofibromas. Am. J. Med. Genet.89(1), 31-37 (1999).
8. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res.62(5), 1573-1577 (2002).
9. Listernick R, Charrow J, Greenwald M et al.Optic gliomas in children with neurofibromatosis type 1. J. Pediatr.114, 788-792 (1989).
10. Listernick R, Charrow J, Greenwald M et al.Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J. Pediatr.125, 63-66 (1994).
11. Gutmann DH, Rasmussen SA, Wolkenstein P et al.Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neun59, 759-761 (2002).
12. Leonard JR, Perry A, Rubin JB et al.The role of biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology 67,1509-1512 (2006).
13. Listernick R, Louis, DN, Packer RJ et al.Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Task Force. Ann. Neurol.41, 143-149 (1997).
14. Listernick R, Ferner R, Liu GT et al.Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann. Neurol.61, 189-198 (2007). Compilation of the current decision making and treatment of optic pathway gliomas.
15. King AA, Listernick R, Charrow J et al.Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am. J. Med. Genet.122A, 95-99 (2003).
16. Listernick R, Ferner RE, Piersall L et al.Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology63, 1944-1946 (2004).
17. Chateil JF, Sossotte C, Pedespan JM et al.MRI and clinical differences between optic patway tumors in children with and without neurofibromatosis. Br. J. Radiol.74, 24-31 (2001).
18. Rodriguez FJ, Perry A, Gutmann DH et al.Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J. Neuropathol. Exp. Neurol.67(3), 240-249 (2008).
19. Habiby R, Silverman B, Listernick R et al.Precocious puberty in children with neurofibromatosis type 1./. Pediatr.126, 364-367 (1995).
20. Lui GT. Optic gliomas of the anterior visual pathway. Curr. Opin. Ophthalmol.17, 427-431 (2006).
21. Sharif S, Ferner R, Birch JM et al.Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J. Clin. Oncol.24(16), 2570-2575 (2006).
22. Ullrich NJ, Robertson R, Knnamon DD et al.Moyamoya following cranial irradiation for primary brain tumors in children. Neurology68(12) , 932-938 (2007).
23. Ferner RE, Chauduri R, Bingham J et al.MRI in neurofibromatosis 1. The nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairment. J. Neurol. Neurosurg. Psychiatry56, 492-495 (1993).
24. De Bella K, Poskitt K, Szudek J et al.Use of 'unidentified bright objects' on MRI for diagnosis of neurofibromatosis 1 in children. Neurology54, 1646-1651 (2000).
25. Dalla Via P, Opocher E, Pinello ML et al.Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro Oncol.9(4), 430-437(2007).
26. Tow SL, Chandela S, Miller NR et al.Long-term outcome in children with gliomas of the anterior visual pathway. Pediatr. Neurol.28(4), 262-270 (2003